由于RFK Jr. 医疗预约后美国流感疫苗需求下降, CSL 推迟了 Seqirus 的分拆并削减了 2026 年的预期. CSL delays Seqirus spinoff and cuts 2026 outlook due to falling U.S. flu vaccine demand after RFK Jr.'s health appointment.

澳大利亚生物技术CSL推迟了疫苗单位Seqirus的附带成果,并削减了2026年的财政前景,理由是在罗伯特·肯尼迪被任命为卫生秘书后,由于公众信心的转移,美国流感疫苗接种率急剧下降。 Australian biotech CSL has delayed the spinoff of its vaccine unit, Seqirus, and cut its 2026 financial outlook, citing a sharp decline in U.S. flu vaccination rates linked to shifting public confidence following Robert F. Kennedy Jr.'s appointment as health secretary. 该公司将其收入增长预测降至2%-3%,净利润增长降至4%-7%,分别从4%-5%和7%-10%分别降至4%-7%-10%,并归因于疫苗需求减少、政策变化和犹豫不断增长。 The company lowered its revenue growth forecast to 2%-3% and net profit growth to 4%-7%, down from 4%-5% and 7%-10%, respectively, and attributed the downturn to reduced vaccine demand, policy changes, and growing hesitancy. 在投资者担心增长疲软和股东价值延迟的情况下,股票下降高达16.6%,这是自2018年以来最低的。 Shares dropped as much as 16.6%, their lowest since 2018, amid investor concern over weakened growth and delayed shareholder value.